The difficulties to evaluate putative risks to humans illustrate general problems in the risk assessment and classification of NM.
The 'Cosmetics Regulation' is the first act in Europe that explicitly considers the putative risks from NM on consumers.
Nevertheless, clinicians and researchers should be aware of the putative risks associated with these SNPs, and the uncertainty regarding potential biases in the primary studies.
Cases and controls were interviewed in their homes by trained interviewers using the same questionnaire (addressing known and putative risks for breast cancer) for cases and controls.
A fine, and not always distinguishable line separates protecting participants from unsolicited findings without actionable clinical (or psychological) benefit, and making them aware of putative risks upon which action may be taken.
Clinicians should be not only aware of the putative risks associated with these variants, but also about the substantial uncertainty regarding these associations due to risks of bias in the primary studies.
